

Brandon F Keele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3535521/publications.pdf>

Version: 2024-02-01

97
papers

11,870
citations

61984

43
h-index

33894

99
g-index

101
all docs

101
docs citations

101
times ranked

8875
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7552-7557.	7.1	1,708
2	Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. <i>Science</i> , 2006, 313, 523-526.	12.6	723
3	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009, 206, 1273-1289.	8.5	684
4	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009, 206, 1253-1272.	8.5	562
5	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	3.4	548
6	Immune clearance of highly pathogenic SIV infection. <i>Nature</i> , 2013, 502, 100-104.	27.8	548
7	Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing. <i>Journal of Virology</i> , 2008, 82, 3952-3970.	3.4	540
8	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. <i>Nature</i> , 2014, 511, 601-605.	27.8	422
9	Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants. <i>Journal of Virology</i> , 2009, 83, 3556-3567.	3.4	354
10	Proliferation of latently infected CD4 ⁺ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. <i>Journal of Experimental Medicine</i> , 2017, 214, 959-972.	8.5	327
11	Clonally expanded CD4 ⁺ T cells can produce infectious HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1883-1888.	7.1	302
12	Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1. <i>PLoS Pathogens</i> , 2009, 5, e1000274.	4.7	298
13	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. <i>Journal of Experimental Medicine</i> , 2009, 206, 1117-1134.	8.5	295
14	Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 ⁺ T Lymphocytes and Monocyte-Derived Macrophages. <i>Journal of Virology</i> , 2012, 86, 2715-2728.	3.4	291
15	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. <i>PLoS Pathogens</i> , 2010, 6, e1000890.	4.7	263
16	Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1126-34.	7.1	252
17	Provirus with identical sequences comprise a large fraction of the replication-competent HIV reservoir. <i>PLoS Pathogens</i> , 2017, 13, e1006283.	4.7	209
18	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	30.7	197

#	ARTICLE	IF	CITATIONS
19	Envelope residue 375 substitutions in simian human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	7.1	170
20	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	27.8	140
21	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV _{mac251} Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. <i>Journal of Virology</i> , 2013, 87, 1708-1719.	3.4	130
22	Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy. <i>Journal of Virology</i> , 2016, 90, 1369-1376.	3.4	121
23	Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys. <i>Journal of Virology</i> , 2010, 84, 10406-10412.	3.4	120
24	Quality and quantity of T _{FH} cells are critical for broad antibody development in SHIV _{AD8} infection. <i>Science Translational Medicine</i> , 2015, 7, 298ra120.	12.4	119
25	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	87
26	HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. <i>Journal of Clinical Investigation</i> , 2020, 130, 5847-5857.	8.2	85
27	HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 4629-4642.	8.2	84
28	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. <i>Nature Communications</i> , 2018, 9, 1928.	12.8	83
29	Functional Cure of SIV _{agm} Infection in Rhesus Macaques Results in Complete Recovery of CD4 ⁺ T Cells and Is Reverted by CD8 ⁺ Cell Depletion. <i>PLoS Pathogens</i> , 2011, 7, e1002170.	4.7	82
30	Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 163-168.	1.1	79
31	Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25891-25899.	7.1	78
32	Analysis of immunoglobulin transcripts and hypermutation following SHIV _{AD8} infection and protein-plus-adjuvant immunization. <i>Nature Communications</i> , 2015, 6, 6565.	12.8	77
33	Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , 2017, 13, e1006359.	4.7	77
34	HIV-1-induced AIDS in monkeys. <i>Science</i> , 2014, 344, 1401-1405.	12.6	76
35	Barriers to mucosal transmission of immunodeficiency viruses. <i>Blood</i> , 2011, 118, 839-846.	1.4	72
36	Comparative Characterization of Transfection- and Infection-Derived Simian Immunodeficiency Virus Challenge Stocks for <i>In Vivo</i> Nonhuman Primate Studies. <i>Journal of Virology</i> , 2013, 87, 4584-4595.	3.4	71

#	ARTICLE	IF	CITATIONS
37	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2975-2980.	7.1	71
38	Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. <i>Virology</i> , 2013, 436, 33-48.	2.4	58
39	Experimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection. <i>Nature Communications</i> , 2015, 6, 8020.	12.8	58
40	Genetic and antigenic features of the transmitted virus. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 352-357.	3.8	53
41	Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIV _{mac251} at Challenge Exposure. <i>Journal of Virology</i> , 2013, 87, 3538-3548.	3.4	52
42	Tracking the Luminal Exposure and Lymphatic Drainage Pathways of Intravaginal and Intra-rectal Inocula Used in Nonhuman Primate Models of HIV Transmission. <i>PLoS ONE</i> , 2014, 9, e92830.	2.5	50
43	Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIV _{AD8} in Rhesus Macaques: Implications for Use in Vaccine Studies. <i>Journal of Virology</i> , 2012, 86, 8516-8526.	3.4	47
44	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. <i>Cell Host and Microbe</i> , 2014, 16, 412-418.	11.0	47
45	Molecularly Tagged Simian Immunodeficiency Virus SIV _{mac239} Synthetic Swarm for Tracking Independent Infection Events. <i>Journal of Virology</i> , 2014, 88, 8077-8090.	3.4	46
46	Intestinal damage precedes mucosal immune dysfunction in SIV infection. <i>Mucosal Immunology</i> , 2018, 11, 1429-1440.	6.0	46
47	HIV Infected T Cells Can Proliferate in vivo Without Inducing Expression of the Integrated Provirus. <i>Frontiers in Microbiology</i> , 2019, 10, 2204.	3.5	46
48	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	45
49	Effect of Suberoylanilide Hydroxamic Acid (SAHA) Administration on the Residual Virus Pool in a Model of Combination Antiretroviral Therapy-Mediated Suppression in SIV _{mac239} -Infected Indian Rhesus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6790-6806.	3.2	43
50	Identifying and characterizing recently transmitted viruses. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 327-334.	3.8	41
51	Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 546-554.	3.8	40
52	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	3.4	40
53	Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. <i>Mucosal Immunology</i> , 2012, 5, 41-52.	6.0	39
54	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	39

#	ARTICLE	IF	CITATIONS
73	CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	18
74	Predictors of SIV recrudescence following antiretroviral treatment interruption. <i>ELife</i> , 2019, 8, .	6.0	18
75	Restricted Replication of Xenotropic Murine Leukemia Virus-Related Virus in Pigtailed Macaques. <i>Journal of Virology</i> , 2012, 86, 3152-3166.	3.4	16
76	Adoptive Transfer of Engineered Rhesus Simian Immunodeficiency Virus-Specific CD8 ⁺ T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques. <i>Journal of Virology</i> , 2016, 90, 9942-9952.	3.4	14
77	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10504-10509.	7.1	14
78	Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	13
79	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. <i>Journal of Virology</i> , 2018, 92, .	3.4	12
80	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. <i>Nature Communications</i> , 2017, 8, 15740.	12.8	11
81	Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes. <i>Journal of Virology</i> , 2019, 93, .	3.4	11
82	Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
83	Blocking $\alpha 4 \beta 7$ integrin delays viral rebound in SHIV _{SF162P3} -infected macaques treated with anti-HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	11
84	Mitigation of endemic GI-tract pathogen-mediated inflammation through development of multimodal treatment regimen and its impact on SIV acquisition in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009565.	4.7	10
85	Genetically barcoded SIV reveals the emergence of escape mutations in multiple viral lineages during immune escape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 494-502.	7.1	9
86	Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation. <i>Nature Communications</i> , 2020, 11, 5412.	12.8	9
87	Transcription Start Site Heterogeneity and Preferential Packaging of Specific Full-Length RNA Species Are Conserved Features of Primate Lentiviruses. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	8
88	Ultrasensitive Immunoassay for Simian Immunodeficiency Virus p27 ^{CA} . <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 993-1001.	1.1	7
89	Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice. <i>Journal of Virology</i> , 2020, 94, .	3.4	7
90	Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir. <i>PLoS Pathogens</i> , 2021, 17, e1009686.	4.7	7

#	ARTICLE	IF	CITATIONS
91	Generation and characterization of a SIVmac239 clone corrected at four suboptimal nucleotides. <i>Retrovirology</i> , 2015, 12, 49.	2.0	6
92	CpG Methylation Profiles of HIV-1 Proviral DNA in Individuals on ART. <i>Viruses</i> , 2021, 13, 799.	3.3	6
93	Low-level alternative tRNA priming of reverse transcription of HIV-1 and SIV in vivo. <i>Retrovirology</i> , 2019, 16, 11.	2.0	3
94	Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses. <i>Clinical Infectious Diseases</i> , 2019, 69, 1460-1461.	5.8	2
95	Lack of Specific Regulatory T Cell Depletion and Cyto-reduction Associated with Extensive Toxicity After Administration of Low and High Doses of Cyclophosphamide. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 45-49.	1.1	1
96	Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2020, 287, 20200354.	2.6	1
97	The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth. <i>PLoS ONE</i> , 2021, 16, e0260010.	2.5	1